Technology

Pro Bono Bio has acquired and developed proprietary technologies to create new medical devices and drug and protein management solutions.

  • Unique core disruptive technology platforms and IP; Sequessomes, Tethersomes, Chaperones and Transfersomes
  • Proprietary technology developed at a cost of over $250m
  • Specific proprietary product technologies protected by patents and patent applications giving cover for more than 15 years
  • Over 2000 people in over 20 successful clinical trials with products